Curated News
By: NewsRamp Editorial Staff
March 26, 2026
Okogen Acquires Ranpirnase Assets, Expands Antiviral Pipeline Across Multiple Therapeutic Areas
TLDR
- Okogen's acquisition of ranpirnase assets from Orgenesis strengthens its lead in antiviral therapeutics, potentially capturing market share in ocular infections and high-consequence pathogen treatments.
- Okogen acquired ranpirnase intellectual property from Orgenesis, expanding its pipeline into ophthalmology, systemic diseases, dermatology, and medical countermeasures through a host-directed antiviral mechanism.
- This acquisition advances treatments for conjunctivitis and high-consequence pathogens like Marburg virus, potentially improving global health outcomes and pandemic preparedness.
- Ranpirnase disrupts viral replication by degrading RNA inside cells, offering a novel approach that could work against diverse viruses including influenza and RSV.
Impact - Why it Matters
This acquisition matters because it represents a significant advancement in antiviral therapeutics with potential implications for public health across multiple disease areas. For patients suffering from acute infectious conjunctivitis, OKG-0303 could provide the first comprehensive treatment addressing both viral and bacterial causes, potentially reducing treatment complexity and improving outcomes. More broadly, ranpirnase's host-directed mechanism offers a promising approach to combating viral resistance, a growing problem with current antiviral therapies. The expansion into medical countermeasures for high-consequence pathogens like filoviruses addresses critical preparedness gaps for potential pandemic threats, while the dermatology and respiratory virus applications could benefit millions affected by common viral infections. This strategic move positions Okogen to address multiple unmet medical needs with a single therapeutic platform, potentially accelerating development timelines across different indications.
Summary
In a strategic move that reshapes its antiviral development pipeline, Okogen Inc. has announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. This acquisition significantly strengthens Okogen's lead ophthalmic program and establishes a robust foundation for the company's expansion into new therapeutic areas. The deal transforms Okogen's development strategy, creating core pillars focused on eyecare, systemic infectious diseases, dermatology, and critical medical countermeasures for high-consequence pathogens like filoviruses. To view the full announcement, including downloadable images, bios, and more, interested parties can click here for comprehensive details about this transformative acquisition.
The company is prioritizing the rapid advancement of its lead ranpirnase program, OKG-0303, an investigational therapy targeting acute infectious conjunctivitis. This focus addresses a significant unmet medical need in a disease area where current treatment remains fragmented, with no single therapy effectively addressing both viral and bacterial causes of the condition. Beyond ophthalmology, Okogen is advancing ranpirnase as a potential antiviral medical countermeasure, engaging with U.S. and international government agencies to evaluate its efficacy against dangerous pathogens like Marburg and Sudan viruses. The company is also progressing parallel research in respiratory viruses including influenza and RSV, demonstrating ranpirnase's broad therapeutic potential across multiple viral threats.
Ranpirnase represents a scientifically differentiated approach to antiviral development as a ribonuclease enzyme that disrupts viral replication through a host-directed mechanism. By degrading intracellular RNA involved in protein synthesis, the molecule creates a translational bottleneck that limits production of viral proteins required for replication. This mechanism targets a host process essential to viral propagation, potentially reducing susceptibility to the resistance problems commonly observed with traditional direct-acting antivirals. With clinical evaluation involving more than 1,000 patients generating substantial safety and translational data, ranpirnase offers a promising platform for addressing multiple viral challenges across different medical specialties.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Okogen Acquires Ranpirnase Assets, Expands Antiviral Pipeline Across Multiple Therapeutic Areas
